Welcome to our dedicated page for Inhibitor Therapeutics SEC filings (Ticker: INTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Inhibitor Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Inhibitor Therapeutics's regulatory disclosures and financial reporting.
Inhibitor Therapeutics, Inc. (INTI) reported the results of its 2026 Annual Meeting of Stockholders held on September 15, 2026. Stockholders elected six directors — Francis E. O’Donnell, Samuel J. Sears, Niraj Vasisht, Michelle Yanez, Michael Jerman and Ronald E. Osman — each to serve a one-year term expiring at the 2027 annual meeting.
Stockholders ratified the appointment of Cherry Bekaert LLP as independent registered public accounting firm for the year ending December 31, 2026. They also approved the 2025 Share Incentive Plan, and, in a non-binding advisory vote, approved the Company’s executive compensation. In addition, stockholders indicated a preferred frequency of future say-on-pay votes of both one year and three years, with the largest support for a three-year frequency.
Inhibitor Therapeutics, Inc. is holding a completely virtual annual stockholders meeting on September 15, 2026 at 10 a.m. Eastern via webcast. Holders of common stock as of July 20, 2026 (when 173,791,968 shares were outstanding) may vote.
Stockholders are asked to elect six incumbent directors, ratify Cherry Bekaert LLP as auditor for 2026, approve the 2025 Equity Incentive Plan, approve executive compensation on an advisory basis, choose the frequency of future say-on-pay votes, and authorize possible adjournment to solicit additional proxies. The 2025 plan reserves up to 20,000,000 shares plus an annual evergreen increase through 2035 and includes multiple award types.
The CEO’s annual base salary is $598,000, and the interim CFO’s base salary is $200,000. Cherry Bekaert billed $72,650 in audit fees and $6,825 in tax fees for 2025. The board recommends voting for all director nominees, all management proposals, and a three‑year say‑on‑pay frequency.
Inhibitor Therapeutics, Inc. reported no revenue and a net loss of $1.3 million for the six months ended June 30, 2026, similar to 2025. Operating cash outflow was $1.9 million, leaving cash of $515,758 and total assets of $637,190 versus liabilities of $3.2 million, including $3.0 million of non‑current deferred revenue. The company states that these conditions raise substantial doubt about its ability to continue as a going concern.
The company depends on advancing itraconazole for basal cell carcinoma nevus syndrome. During 2026 it shifted its proposed primary efficacy endpoint to the rate and response of surgically eligible basal cell carcinomas and requested FDA feedback via a Type C meeting, with written responses expected by the end of September 2026. A pilot bioavailability study showed the Avior-developed 75 mg itraconazole capsule had pharmacokinetics generally comparable to TOLSURA, and a provisional U.S. patent application was filed for the amorphous nano/microparticle formulation. Itraconazole holds FDA Orphan Drug Designation for BCCNS. A February 2026 securities purchase agreement for $3.0 million remains unfunded; the company has obtained a default judgment and is pursuing collection, but has not recorded any receivable.
Black Robe Capital LLC, a 10% owner of Inhibitor Therapeutics, Inc., together with Chief Financial Officer James A. McNulty as reporting persons, recorded a bona fide gift of 3,200,000 shares of common stock on July 1, 2026. Following this disposition, the reporting holder directly owned 19,901,057 common shares.
OSMAN RONALD E reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. reported that director and ten percent owner Ronald E. Osman received a grant of 50,000 shares of restricted common stock on May 4, 2026 as compensation under the 2014 Equity Incentive Plan, subject to shareholder approval. After this award, reported indirect ownership totals 23,614,985 common shares, consisting of 100,000 shares held by Mr. Osman and the remaining shares held by the Ronald E. Osman Trust III, for which he serves as sole trustee.
Yanez Michelle reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. director Michelle Yanez received a grant of 50,000 shares of restricted common stock on May 4, 2026 as compensation under the company’s 2025 Equity Incentive Plan, subject to shareholder approval, increasing her direct holdings to 1,221,271 common shares.
SEARS SAMUEL P JR reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. director Samuel P. Sears Jr. received a grant of 50,000 shares of restricted common stock on May 4, 2026 as compensation under the 2025 Equity Incentive Plan, subject to shareholder approval. After this award, he directly holds 1,229,543 common shares.
ODONNELL FRANCIS E JR reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. reported that Chief Executive Officer Francis E. O'Donnell Jr. received a grant of 50,000 shares of restricted common stock on May 4, 2026, at $0.00 per share as compensation under the 2025 Equity Incentive Plan, subject to shareholder approval. Following this award, he directly holds a total of 150,000 common shares.
Jerman Michael Allen reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. director Jerman Michael Allen received a grant of 50,000 shares of restricted common stock as compensation under the company’s 2025 Equity Incentive Plan. Following this award, he directly holds 180,411 shares of common stock, reflecting a routine equity-based compensation grant rather than an open-market trade.
Vasisht Niraj reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. director Niraj Vasisht received a grant of 50,000 shares of restricted common stock as compensation under the company’s 2025 Equity Incentive Plan. The grant was recorded at a price of $0.00 per share, and his directly held common stock position increased to 200,000 shares following this award.